SYSTEMATIC REVIEW
High-density lipoprotein cholesterol and multiple sclerosis: a systematic review and meta-analysis
1
School of Medicine, National and Kapodistrian University of Athens, Athens, Greece
2
School of Medicine, European University Cyprus, Nicosia, Cyprus
3
1st Department of Internal Medicine, University Hospital of Ioannina, Faculty of Medicine, University of Ioannina, Ioannina, Greece
4
Department of Nursing, School of Health Sciences, University of Ioannina, Ioannina, Greece
5
Department of Internal Medicine, German Medical Institute, Limassol, Cyprus
These authors had equal contribution to this work
Submission date: 2025-01-18
Acceptance date: 2025-05-01
Publication date: 2025-06-02
Corresponding author
Aris P. Agouridis
School of Medicine European University Cyprus, Nicosia Department of Internal Medicine German Medical Institute Limassol, Cyprus
School of Medicine European University Cyprus, Nicosia Department of Internal Medicine German Medical Institute Limassol, Cyprus
Arch Med Sci Atheroscler Dis 2025;10(1):69-77
KEYWORDS
TOPICS
ABSTRACT
Introduction:
Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system characterized by demyelination and axonal degeneration. Evidence has shown that lipid metabolism is associated with MS clinical outcomes. The aim was to systematically investigate the association between high-density lipoprotein cholesterol (HDL-C) and disease activity in MS.
Material and methods:
Medline via PubMed, the Cochrane Library and Clinicaltrials.gov databases were searched for studies with data on HDL-C in patients with MS. A qualitative synthesis of published prospective and retrospective studies on the role of HDL-C and other lipid profile parameters in MS was performed. Additionally, a meta-analysis on HDL-C mean differences (MD) between relapsing remitting MS (RRMS) cases and healthy controls (HC) was performed.
Results:
Literature search identified 13 eligible studies evaluating the HDL-C levels of RRMS patients. In total, 1692 participants were included, 859 of which were RRMS patients, and 833 were HC. The pooled analysis demonstrated that RRMS patients had significantly lower HDL-C levels compared with HC (MD: –3.35 mg/dl, 95% CI (–5.69, –1.01), p = 0.005). Regarding triglycerides (TG) and total cholesterol (TC), the pooled analysis from 11 and 13 studies, respectively, showed significantly higher TG (MD = 26.33, 95% CI (15.03, 37.62), p < 0.00001) and TC levels (MD = 11.03, 95% CI (0.45, 21.60), p = 0.04) in RRMS versus HC. No significant differences were observed in low-density lipoprotein cholesterol levels between RRMS and HC.
Conclusions:
HDL-C levels were significantly decreased in RRMS patients compared with HC. HDL-C and other lipid profile parameters should be considered in the assessment of patients with RRMS.
Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system characterized by demyelination and axonal degeneration. Evidence has shown that lipid metabolism is associated with MS clinical outcomes. The aim was to systematically investigate the association between high-density lipoprotein cholesterol (HDL-C) and disease activity in MS.
Material and methods:
Medline via PubMed, the Cochrane Library and Clinicaltrials.gov databases were searched for studies with data on HDL-C in patients with MS. A qualitative synthesis of published prospective and retrospective studies on the role of HDL-C and other lipid profile parameters in MS was performed. Additionally, a meta-analysis on HDL-C mean differences (MD) between relapsing remitting MS (RRMS) cases and healthy controls (HC) was performed.
Results:
Literature search identified 13 eligible studies evaluating the HDL-C levels of RRMS patients. In total, 1692 participants were included, 859 of which were RRMS patients, and 833 were HC. The pooled analysis demonstrated that RRMS patients had significantly lower HDL-C levels compared with HC (MD: –3.35 mg/dl, 95% CI (–5.69, –1.01), p = 0.005). Regarding triglycerides (TG) and total cholesterol (TC), the pooled analysis from 11 and 13 studies, respectively, showed significantly higher TG (MD = 26.33, 95% CI (15.03, 37.62), p < 0.00001) and TC levels (MD = 11.03, 95% CI (0.45, 21.60), p = 0.04) in RRMS versus HC. No significant differences were observed in low-density lipoprotein cholesterol levels between RRMS and HC.
Conclusions:
HDL-C levels were significantly decreased in RRMS patients compared with HC. HDL-C and other lipid profile parameters should be considered in the assessment of patients with RRMS.
REFERENCES (46)
1.
Walton C, King R, Rechtman L, et al. Rising prevalence of multiple sclerosis worldwide: insights from the Atlas of MS, third edition. Mult Scler 2020; 26: 1816-21.
2.
Global, regional, and national burden of disorders affecting the nervous system, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021. Lancet Neurol 2024; 23: 344-81.
3.
Filippi M, Bar-Or A, Piehl F, et al. Multiple sclerosis. Nat Rev Dis Primers 2018; 4: 43.
4.
Lorincz B, Jury EC, Vrablik M, Ramanathan M, Uher T. The role of cholesterol metabolism in multiple sclerosis: from molecular pathophysiology to radiological and clinical disease activity. Autoimmun Rev 2022; 21: 103088.
5.
Albuquerque LDS, Damasceno NRT, Maia FN, et al. Cardiovascular risk estimated in individuals with multiple sclerosis: a case-control study. Mult Scler Relat Disord 2021; 54: 103133.
6.
Vollmer T, Key L, Durkalski V, et al. Oral simvastatin treatment in relapsing-remitting multiple sclerosis. Lancet 2004; 363: 1607-8.
7.
Almramhi MM, Finan C, Storm CS, et al. Exploring the role of plasma lipids and statin interventions on multiple sclerosis risk and severity: a mendelian randomization study. Neurology 2023; 101: e1729-40.
8.
Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021; 372: n71.
9.
Wells GA, Shea B, O’Connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. 2013.
10.
McGrath S, Zhao X, Steele R, Thombs BD, Benedetti A. Estimating the sample mean and standard deviation from commonly reported quantiles in meta-analysis. Stat Methods Med Res 2020; 29: 2520-37.
11.
Ferretti G, Bacchetti T, Principi F, et al. Increased levels of lipid hydroperoxides in plasma of patients with multiple sclerosis: a relationship with paraoxonase activity. Mult Scler 2005; 11: 677-82.
12.
Jamroz-Wisniewska A, Beltowski J, Stelmasiak Z, Bartosik-Psujek H. Paraoxonase 1 activity in different types of multiple sclerosis. Mult Scler 2009; 15: 399-402.
13.
Li Y, Wang H, Hu X, Peng F, Yang Y. Serum lipoprotein levels in patients with neuromyelitis optica elevated but had little correlation with clinical presentations. Clin Neurol Neurosurg 2010; 112: 478-81.
14.
Moghtaderi A, Hashemi M, Sharafaddinzadeh N, et al. Lack of association between paraoxonase 1 Q192R polymorphism and multiple sclerosis in relapse phase: a case-control study. Clin Biochem 2011; 44: 795-8.
15.
Palavra F, Marado D, Mascarenhas-Melo F, et al. New markers of early cardiovascular risk in multiple sclerosis patients: oxidized-LDL correlates with clinical staging. Dis Markers 2013; 34: 341-8.
16.
Penesova A, Vlcek M, Imrich R, et al. Hyperinsulinemia in newly diagnosed patients with multiple sclerosis. Metab Brain Dis 2015; 30: 895-901.
17.
Mukhopadhyay S, Fellows K, Browne RW, et al. Interdependence of oxysterols with cholesterol profiles in multiple sclerosis. Mult Scler 2017; 23: 792-801.
18.
Jorissen W, Wouters E, Bogie JF, et al. Relapsing-remitting multiple sclerosis patients display an altered lipoprotein profile with dysfunctional HDL. Sci Rep 2017; 7: 43410.
19.
Ďurfinová M, Procházková Ľ, Petrleničová D, et al. Cholesterol level correlate with disability score in patients with relapsing-remitting form of multiple sclerosis. Neurosci Lett 2018; 687: 304-7.
20.
Gafson AR, Thorne T, McKechnie CIJ, Jimenez B, Nicholas R, Matthews PM. Lipoprotein markers associated with disability from multiple sclerosis. Sci Rep 2018; 8: 17026.
21.
Jakimovski D, Zivadinov R, Pelizzari L, Browne RW, Weinstock-Guttman B, Ramanathan M. Lipoprotein(a) levels are associated with the size of extracranial arteries in multiple sclerosis. J Vasc Res 2020; 57: 16-23.
22.
Gezmis H, Mayda Domac F, Ormeci B, et al. (2), (3), and(4) variants of ApoE; rs2228570 (VDR), rs4588 and rs7041 (VDBP) polymorphisms in patients with multiple sclerosis: a case-control study in Turkish population. Int J Clin Pract 2021; 75: e14801.
23.
Boshra H, Awad M, Hussein M, Elyamani E. Vascular dysfunction and dyslipidemia in multiple sclerosis: are they correlated with disease duration and disability status? Egypt Heart J 2022; 74: 9.
24.
Giubilei F, Antonini G, Di Legge S, et al. Blood cholesterol and MRI activity in first clinical episode suggestive of multiple sclerosis. Acta Neurol Scand 2002; 106: 109-12.
25.
Salemi G, Gueli MC, Vitale F, et al. Blood lipids, homocysteine, stress factors, and vitamins in clinically stable multiple sclerosis patients. Lipids Health Dis 2010; 9: 19.
26.
Keytsman C, Eijnde BO, Hansen D, Verboven K, Wens I. Elevated cardiovascular risk factors in multiple sclerosis. Mult Scler Relat Disord 2017; 17: 220-3.
27.
Radikova Z, Penesova A, Vlcek M, et al. LDL and HDL lipoprotein subfractions in multiple sclerosis patients with decreased insulin sensitivity. Endocr Regul 2018; 52: 139-45.
28.
Murali N, Browne RW, Fellows Maxwell K, et al. Cholesterol and neurodegeneration: longitudinal changes in serum cholesterol biomarkers are associated with new lesions and gray matter atrophy in multiple sclerosis over 5 years of follow-up. Eur J Neurol 2020; 27: 188-e4.
29.
Rádiková Ž, Penesová A, Vlček M, et al. Lipoprotein profiling in early multiple sclerosis patients: effect of chronic inflammation? Lipids Health Dis 2020; 19: 49.
30.
Ulusoy EK, Bolattürk Ö F, Göl MF. Relation between the novel marker monocyte to high-density lipoprotein cholesterol ratio and severity in multiple sclerosis. Ann Indian Acad Neurol 2020; 23: 275-9.
31.
Nieste I, Franssen WMA, Duvivier B, Spaas J, Savelberg H, Eijnde BO. Replacing sitting with light-intensity physical activity throughout the day versus 1 bout of vigorous-intensity exercise: similar cardiometabolic health effects in multiple sclerosis. A randomised cross-over study. Disabil Rehabil 2023; 45: 3293-302.
32.
Siddiqui K, Browne RW, Benedict RHB, et al. Cholesterol pathway biomarkers are associated with neuropsychological measures in multiple sclerosis. Mult Scler Relat Disord 2023; 69: 104374.
33.
Katsiki N, Filippatos T, Vlachopoulos C, et al. Executive summary of the Hellenic Atherosclerosis Society guidelines for the diagnosis and treatment of dyslipidemias - 2023. Atheroscler Plus 2024; 55: 74-92.
34.
Sosnowska B, Stepinska J, Mitkowski P, et al. Recommendations of the Experts of the Polish Cardiac Society (PCS) and the Polish Lipid Association (PoLA) on the diagnosis and management of elevated lipoprotein(a) levels. Arch Med Sci 2024; 20: 8-27.
35.
Fellows K, Uher T, Browne RW, et al. Protective associations of HDL with blood-brain barrier injury in multiple sclerosis patients. J Lipid Res 2015; 56: 2010-8.
36.
Davalos D, Ryu JK, Merlini M, et al. Fibrinogen-induced perivascular microglial clustering is required for the development of axonal damage in neuroinflammation. Nat Commun 2012; 3: 1227.
37.
Feingold KR, Grunfeld C. Effect of inflammation on HDL structure and function. Curr Opin Lipidol 2016; 27: 521-30.
38.
Moutzouri E, Elisaf M, Liberopoulos EN. Hypocholesterolemia. Curr Vasc Pharmacol 2011; 9: 200-12.
39.
Filippas-Ntekouan S, Liberopoulos E, Elisaf M. Lipid testing in infectious diseases: possible role in diagnosis and prognosis. Infection 2017; 45: 575-88.
40.
Agouridis AP, Liberopoulos EN, Kostapanos MS, Elisaf MS. New-onset extremely low levels of high-density lipoprotein cholesterol. J Clin Lipidol 2012; 6: 593-5.
41.
Agouridis AP, Pagkali A, Zintzaras E, Rizos EC, Ntzani EE. High-density lipoprotein cholesterol: a marker of COVID-19 infection severity? Atheroscler Plus 2021; 44: 1-9.
42.
Makris A, Pagkali A, Nikolousis E, Filippatos TD, Agouridis AP. High-density lipoprotein cholesterol and multiple myeloma: a systematic review and meta-analysis. Atheroscler Plus 2023; 54: 7-13.
43.
Mincu RI, Magda LS, Florescu M, et al. Cardiovascular dysfunction in multiple sclerosis. Maedica (Bucur) 2015; 10: 364-70.
44.
Palladino R, Marrie RA, Majeed A, Chataway J. Evaluating the risk of macrovascular events and mortality among people with multiple sclerosis in England. JAMA Neurol 2020; 77: 820-8.
45.
Chataway J, Schuerer N, Alsanousi A, et al. Effect of high-dose simvastatin on brain atrophy and disability in secondary progressive multiple sclerosis (MS-STAT): a randomised, placebo-controlled, phase 2 trial. Lancet 2014; 383: 2213-21.
46.
Framke E, Thygesen LC, Malmborg M, Schou M, Sellebjerg F, Magyari M. Risk of cardiovascular disease in patients with multiple sclerosis treated with fingolimod compared to natalizumab: a nationwide cohort study of 2095 patients in Denmark. Mult Scler 2024; 30: 184-91.
Share
RELATED ARTICLE
| ISSN: | 2451-0629 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
